New Drugs and Gene Therapy: Could One Help Your Child?
The short answer: as of today, no drug cures Duchenne muscular dystrophy (DMD). What the new drugs can do is slow things down, or improve some functions a little — and every one of them has…
What parents ask most “My son has a deletion of exons 45–50. Can he use an exon-skipping drug, or is gene therapy his only hope?” “Elevidys costs about $3.2 million a shot. How long does it actually last? Does it cure him? And if he has it, can he still have another gene therapy later?” “He can't walk any more. Can he still have it? How real is the liver risk?” “Can givinostat be used with any mutation? People say SAT-3247 can regrow muscle — is that believable? And where have China's own drugs, BBM-D101 and HG302, got to?”
The short answer: as of today, no drug cures Duchenne muscular dystrophy (DMD). What the new drugs can do is slow things down, or improve some functions a little — and every one of them has hard entry rules. Age, whether he can still walk, the type of mutation, and whether he already has antibodies to the virus used: miss one, and the drug is not an option. Just as important, there were serious safety events through 2025 and into 2026. On this topic, “wait and look carefully” can matter as much as “hurry up.”
First, keep the different kinds of drug separate
Gene therapy (Elevidys) delivers a shortened version of the dystrophin gene into the body using an AAV virus vector, in a single intravenous infusion. It was approved in the US in 2023 and priced at about $3.2 million per treatment. But its Phase III EMBARK trial did not meet its main endpoint at 52 weeks — the North Star Ambulatory Assessment (NSAA) score did not improve by a statistically significant amount. Secondary measures, such as time to rise from the floor and the 10-metre walk, did show clinically meaningful improvement. In plain terms: there are signs it helps, but not as certainly as the headlines suggest. On 14 November 2025, the US Food and Drug Administration (FDA) added a boxed warning — its strongest warning — for acute serious liver injury and acute liver failure, and removed the indication for patients who cannot walk. It is now limited to ambulatory children aged 4 and over. After one dose, the body develops antibodies, so the same kind of gene therapy generally cannot be given again. In the trial-decision research, that was the point parents wrestled with most.
Exon-skipping drugs only work if the mutation matches, and together they cover only about three in ten patients. Eteplirsen, which skips exon 51, covers about 13%. Golodirsen and viltolarsen, which skip exon 53, cover about 8%–10%. Casimersen, which skips exon 45, covers about 8%. All of them are given as a weekly intravenous infusion, long term. If your child has a deletion such as exons 46–50, check his genetic report drug by drug. Do not assume he qualifies just because another family says skipping drugs “work.”
Givinostat was approved by the FDA in March 2024 for patients aged 6 and over, whatever their mutation. For families whose mutation does not match any skipping drug, that is genuinely good news. Its EPIDYS trial enrolled 179 people, and its main endpoint was the time taken to climb four stairs after 18 months. It is normally used alongside a steroid, not instead of one.
SAT-3247, whose generic name is forazapadin, is an oral small-molecule drug from Satellos, a Canadian company. Its target is AAK1. The idea is not to replace dystrophin, but to restore the ability of muscle stem cells to regenerate. In adult Phase Ib data, grip strength improved by an average of 118.6% in the dominant hand and 97.9% in the non-dominant hand, and forced vital capacity improved by 5.8%. The numbers of people involved were still very small, so treat this as an early signal, nothing more. The paediatric Phase II BASECAMP trial enrolled 51 ambulatory boys aged 7 to under 10. The first child was dosed on 12 February 2026, and top-line results are expected in the fourth quarter of 2026. The drug has FDA Fast Track status. A chemical formula circulating online is not the same as being able to copy the drug, and it certainly does not mean a copy would be safe to give anyone.
The China pipeline — and a risk that has to be said out loud
Domestic work is moving. Belief Biomed's BBM-D101, an AAV gene therapy, received Investigational New Drug (IND) clearance from China's National Medical Products Administration (NMPA) in April 2025 — it had already received FDA IND clearance in January — for boys aged 4–9. The first child in its registration trial was dosed at Peking Union Medical College Hospital in August–September 2025.
A case every parent should know Huida Gene's HG302, a CRISPR gene-editing therapy, enrolled only four boys aged 4–8 in an investigator-initiated trial. One boy in the high-dose group died about 81 hours after dosing, from acute respiratory distress syndrome triggered by severe activation of the complement system and cytokines. Recruitment has stopped. The lesson is simple: a clinical trial is not just “getting a new drug for free.” It carries real risk, including fatal risk. Before you sign up, ask what phase the trial is in, which dose group your child would be in, what serious side effects have already happened, how you can withdraw, and what treatment and compensation are in place if something goes wrong.
In China | Abroad
No DMD gene therapy or exon-skipping drug is approved for sale in mainland China. In practice, parents have two routes: watch closely for domestic trial recruitment, or seek treatment overseas — and with the second, think through the cost, the follow-up care, and what protection you have if something goes wrong, before you go. | The US has the widest choice: Elevidys, four exon-skipping drugs and givinostat. Europe has been more cautious. The European Medicines Agency's human medicines committee recommended against conditional approval of Elevidys, and the European Commission adopted that position in September 2025; exon-skipping drugs have also been refused by the EMA in the past. Japan added Elevidys to its National Health Insurance on 20 February 2026, but with detailed conditions: aged 3 to under 8, still walking, negative for anti-AAVrh74 antibodies, and no deletion of exon 8 or 9.
What you can do now
Get out your child's genetic test report and check that the mutation is written in full. This report is the starting point for judging every new drug. If it is vague, go back to the hospital and have it completed or re-read.
Every time you see a “new drug approved” headline, ask four questions: Which country approved it? For what ages? Does the child have to be able to walk? Does my child's mutation match? If any one answer is no, set it aside for now.
If you want to join a trial, check its status on an official registry first, then contact the trial centre directly and ask about the entry criteria. Never sign up through an agent, and never pay anyone who promises you a place.
Gene therapy is a one-time decision. Before you go ahead, talk through “after this, he cannot have the same kind of drug again” properly with the doctor, and be sure that now really is the right time.
What it costs Elevidys is priced at about $3.2 million per treatment in the US. In Japan, its National Health Insurance price is ¥304,972,042 (about $2 million), but Japan's high-cost medical expense system caps what families pay: for a middle-income household, roughly ¥87,000–90,000 a month out of pocket. If a family in China is thinking about treatment overseas, do not budget on the price of one injection alone. Testing, hospital stays, long-term follow-up and travel all have to go in.
Sources for this article
Drugs.com (Elevidys price and use): https://www.drugs.com/medical-answers/how-elevidys-cost-3577480/ ; Aetna clinical policy bulletin (FDA label revision and boxed warning): https://www.aetna.com/cpb/medical/data/900_999/0911.html
Chugai press release, 20 Feb 2026 (Japan launch, insurance price and EMBARK results), checked directly: https://www.chugai-pharm.co.jp/news/cont_file_dl.php?f=260220_eElevidys_Launch.pdf&src=[%0],[%1]&rep=130,1229
University of Hong Kong, Department of Paediatrics neuromuscular diseases page (exon-skipping coverage): http://paed.hku.hk/website/nmd/DMD.html ; Wikipedia, “Givinostat” (EPIDYS trial): https://en.wikipedia.org/wiki/Givinostat
SAT-3247 / BASECAMP progres
